PE20170290A1 - Vacunas contra virus de influenza y usos de las mismas - Google Patents
Vacunas contra virus de influenza y usos de las mismasInfo
- Publication number
- PE20170290A1 PE20170290A1 PE2017000042A PE2017000042A PE20170290A1 PE 20170290 A1 PE20170290 A1 PE 20170290A1 PE 2017000042 A PE2017000042 A PE 2017000042A PE 2017000042 A PE2017000042 A PE 2017000042A PE 20170290 A1 PE20170290 A1 PE 20170290A1
- Authority
- PE
- Peru
- Prior art keywords
- influenza
- polypeptide
- influenza viruses
- vaccines against
- against influenza
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 5
- 241000700605 Viruses Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 101710154606 Hemagglutinin Proteins 0.000 abstract 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 3
- 101710176177 Protein A56 Proteins 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un polipeptido de dominio de tallo de hemaglutinina de influenza que comprende: a) un dominio de hemaglutinina de influenza HA1 que comprende un segmento de tallo N-terminal de HA1 unido covalentemente a un segmento de tallo C-terminal de HA1; b) un dominio de hemaglutinina de influenza HA2 unido al segmento C-terminal de HA1; y c) el polipeptido no comprende sitios de escision de proteasa en la union entre los dominios de HA1 y HA2; entre otros. Dicho polipeptido es util en la deteccion, tratamiento o prevencion de la influenza
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14176451 | 2014-07-10 | ||
US201462062746P | 2014-10-10 | 2014-10-10 | |
EP14195133 | 2014-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170290A1 true PE20170290A1 (es) | 2017-03-26 |
Family
ID=55063615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017000042A PE20170290A1 (es) | 2014-07-10 | 2015-07-09 | Vacunas contra virus de influenza y usos de las mismas |
Country Status (16)
Country | Link |
---|---|
US (2) | US10111944B2 (es) |
EP (2) | EP3587442A1 (es) |
JP (1) | JP6735269B2 (es) |
KR (1) | KR102461538B1 (es) |
CN (1) | CN106661091B (es) |
AU (1) | AU2015286721B2 (es) |
BR (1) | BR112017000257A2 (es) |
CA (1) | CA2952351C (es) |
CL (1) | CL2017000063A1 (es) |
EA (1) | EA038400B1 (es) |
MX (1) | MX2017000394A (es) |
MY (1) | MY187261A (es) |
PE (1) | PE20170290A1 (es) |
PH (1) | PH12016502500A1 (es) |
SG (1) | SG11201610443WA (es) |
WO (1) | WO2016005480A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
EP3566714A1 (en) | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
AU2013362935B2 (en) | 2012-12-18 | 2018-10-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
EA034639B1 (ru) | 2013-05-30 | 2020-03-02 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
EA035375B1 (ru) | 2014-07-10 | 2020-06-03 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
PE20170290A1 (es) | 2014-07-10 | 2017-03-26 | Janssen Vaccines And Prevention B V | Vacunas contra virus de influenza y usos de las mismas |
AU2016209032A1 (en) | 2015-01-23 | 2017-08-10 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
JP7237344B2 (ja) | 2016-06-15 | 2023-03-13 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルス血球凝集素タンパク質及びその使用 |
WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
HUE059545T2 (hu) | 2018-01-23 | 2022-11-28 | Janssen Vaccines & Prevention Bv | Influenzavírus-vakcinák és alkalmazásaik |
KR20220057578A (ko) | 2019-09-05 | 2022-05-09 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 백신 및 이의 용도 |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
MY183517A (en) | 2009-05-11 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
JP2013526849A (ja) | 2010-03-30 | 2013-06-27 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
CN103906763B (zh) | 2011-07-14 | 2016-10-12 | 克鲁塞尔荷兰公司 | 能够中和***发育群1和***发育群2的a型流感病毒以及b型流感病毒的人结合分子 |
EP3566714A1 (en) * | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
EA034639B1 (ru) * | 2013-05-30 | 2020-03-02 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
PE20170290A1 (es) | 2014-07-10 | 2017-03-26 | Janssen Vaccines And Prevention B V | Vacunas contra virus de influenza y usos de las mismas |
EA035375B1 (ru) | 2014-07-10 | 2020-06-03 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
-
2015
- 2015-07-09 PE PE2017000042A patent/PE20170290A1/es unknown
- 2015-07-09 CN CN201580036947.0A patent/CN106661091B/zh active Active
- 2015-07-09 US US15/324,964 patent/US10111944B2/en active Active
- 2015-07-09 EP EP19184431.5A patent/EP3587442A1/en not_active Withdrawn
- 2015-07-09 JP JP2017500859A patent/JP6735269B2/ja active Active
- 2015-07-09 KR KR1020177003525A patent/KR102461538B1/ko active IP Right Grant
- 2015-07-09 AU AU2015286721A patent/AU2015286721B2/en active Active
- 2015-07-09 EP EP15738027.0A patent/EP3166962B1/en active Active
- 2015-07-09 EA EA201692541A patent/EA038400B1/ru unknown
- 2015-07-09 CA CA2952351A patent/CA2952351C/en active Active
- 2015-07-09 MY MYPI2017700053A patent/MY187261A/en unknown
- 2015-07-09 WO PCT/EP2015/065661 patent/WO2016005480A1/en active Application Filing
- 2015-07-09 BR BR112017000257A patent/BR112017000257A2/pt not_active Application Discontinuation
- 2015-07-09 MX MX2017000394A patent/MX2017000394A/es unknown
- 2015-07-09 SG SG11201610443WA patent/SG11201610443WA/en unknown
-
2016
- 2016-12-14 PH PH12016502500A patent/PH12016502500A1/en unknown
-
2017
- 2017-01-10 CL CL2017000063A patent/CL2017000063A1/es unknown
-
2018
- 2018-09-25 US US16/141,161 patent/US10328144B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2017000394A (es) | 2017-11-30 |
CA2952351C (en) | 2023-10-17 |
SG11201610443WA (en) | 2017-01-27 |
PH12016502500A1 (en) | 2017-03-22 |
CN106661091A (zh) | 2017-05-10 |
MY187261A (en) | 2021-09-16 |
JP6735269B2 (ja) | 2020-08-05 |
AU2015286721B2 (en) | 2019-11-21 |
AU2015286721A1 (en) | 2016-12-22 |
JP2017521425A (ja) | 2017-08-03 |
US20190015500A1 (en) | 2019-01-17 |
US10111944B2 (en) | 2018-10-30 |
EP3166962B1 (en) | 2019-08-21 |
EA201692541A1 (ru) | 2017-05-31 |
EA038400B1 (ru) | 2021-08-23 |
EP3587442A1 (en) | 2020-01-01 |
EP3166962A1 (en) | 2017-05-17 |
KR102461538B1 (ko) | 2022-10-31 |
US10328144B2 (en) | 2019-06-25 |
CN106661091B (zh) | 2020-10-30 |
CA2952351A1 (en) | 2016-01-14 |
KR20170030590A (ko) | 2017-03-17 |
WO2016005480A1 (en) | 2016-01-14 |
CL2017000063A1 (es) | 2017-12-15 |
US20170209564A1 (en) | 2017-07-27 |
BR112017000257A2 (pt) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170290A1 (es) | Vacunas contra virus de influenza y usos de las mismas | |
PE20170291A1 (es) | Vacunas contra virus de influenza y usos de las mismas | |
CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
BR112017017286A2 (pt) | protease de cisteína | |
BR112017017284A2 (pt) | protease de cisteína | |
AR089005A1 (es) | Vacunas contra el virus de la influenza y sus usos | |
EA201592306A1 (ru) | Вакцины против вируса гриппа и их применения | |
ES2682981T3 (es) | Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas | |
EA201591164A1 (ru) | Вакцины против вируса гриппа и их применение | |
AR090392A1 (es) | Vacunas contra el virus de la influenza y sus usos | |
BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
NZ739260A (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
MX2014012285A (es) | Composicion farmaceutica que contiene un inhibidor de serina proteasa para tratar o prevenir infeccion por el virus de la influenza. | |
BR112017005402B8 (pt) | Sistemas de fusão e método de montagem | |
MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
EA201892385A1 (ru) | Модификация сконструированных полипептидов гемагглютинина вируса гриппа | |
MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
MX2021006543A (es) | Vacuna. | |
BR112017005993A2 (pt) | derivados de peptídeo inovadores e usos dos mesmos | |
ZA201700164B (en) | Influenza virus vaccines and uses thereof | |
CU20140061A7 (es) | Vacunas contra virus influenza y sus usos |